RRML - FasL is expressed in human breast cancer endothelia. Who benefits?
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Impact factor (2019): 0.945

Rejection rate (2020): 75%

Română English


Clarivate analytics (ISI) Impact factor


Advanced search


Top 10 downloaded articles
- November 2020 -
 
Molecular epidemiology and the... 13
Antibacterial and antitumor ac... 12
The Diagnostic Value of Monocy... 12
LSM3, NDUFB3, and PTGS2 may be... 11
Assessment of circulating tumo... 11
Romanian Review of Laboratory ... 9
The potential of programmed de... 9
Troubleshootings in RNA extrac... 7
Impact of preanalytical variab... 4
Validation of GOD / PAP method... 3

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 20(1)/2012
XML
TXT

FasL is expressed in human breast cancer endothelia. Who benefits?

Corina M. Cianga, Irina D. Florea, Petru Cianga


Abstract:

Background: Fas ligand (FasL) expression is one of the mechanisms responsible for the “immune privi-lege” of tissues such as testis and eye. Many solid tumors express FasL as an immune escape strategy, aiming to induce apoptosis in Fas-expressing leukocytes, and thus to prevent the accumulation of effector cells. Materials and Methods: We investigated by immunohistochemistry the FasL expression in human breast carcinomas vasculature (blood vessels versus lymphatics), endothelial activation status and markers associated with tumor aggressiveness. Results: We bring evidence of a heterogeneous FasL expression in the human breast carcinomas associated blood vessels, but not lymphatics. The endothelial FasL expression was significantly correlated with the tumor FasL expression, tumor size, the presence of rich vascular networks, and axillary lymph nodes metastases; however, it was not correlated with low tumor invading leukocytes density. Conclusion: Breast carcinomas are among tumors in which the tumor-host interaction is correlated with the clinical outcome, hence understanding the significance of endothelial FasL expression is of outmost importance.

Keywords: FasL,breast carcinoma,endothelium,immune privilege,tolerance

 
  PDF Download full text PDF
(651 KB)
     
 
How to cite
Cianga CM, Florea ID, Cianga P. FasL is expressed in human breast cancer endothelia. Who benefits?. Rev Romana Med Lab. 2012;20(1):45-56